Latest in News & Research
Model, Nomogram Predict Recurrence-Free, Melanoma-Specific Survival
Final model composed of six prognostic factors showed good prediction in development cohort and external validation
Tildrakizumab Efficacious, Safe for Plaque Psoriasis of the Scalp
Significant improvement seen in IGA response and PSSI 90, with no serious treatment-related adverse events
Second Primary Malignancy Risk Increased After Cutaneous B-Cell Lymphoma
Women have increased risk for thyroid, renal, lung cancers; men have highest risk for melanoma, bladder, prostate cancers
Improved Prognosis Seen With Regression of Primary Cutaneous Melanoma
Findings seen in patients with primary cutaneous melanoma undergoing SLN biopsy and those who progressed to unresectable stage
Do Skin Surface Temperature Measures Differ for Cellulitis, Pseudocellulitis?
Researchers find all skin surface temperature measures differ significantly between cellulitis and pseudocellulitis
Social Media + Photo-Editing Apps Tied to Higher Interest in Cosmetic Procedures
Increases seen in social media use and cosmetic consultations during the COVID-19 pandemic
Survey Assesses Perspectives on Patient Image Use in Dermatology
Most patients report an increase in trust in quality of medical care if they were asked for consent to use medical image
Wearable UV Dosimeter May Reduce Nonmelanoma Skin Cancer in Elderly
No significant reduction seen in incidence rates of actinic keratoses; no changes observed in anxiety, depression surveys
AAD: Long-Term Safety, Efficacy Seen for Delgocitinib Cream in Hand Eczema
No safety concerns observed during 36 weeks of treatment with delgocitinib cream 20 mg/g
AAD: Continuous Improvements Seen Through 68 Weeks for Deuruxolitinib in Alopecia
Proportion of patients achieving Severity of Alopecia Tool score ≤20 increased through 68 weeks of open-label extension
Your Go-To Job Board for Critical Dermatology Support Roles
AAD: Hair Regrowth Continues to Improve at 76 Weeks With Baricitinib for Severe Alopecia
Patients achieving SALT score ≤20 increased from 44.5 to 75.8 percent at week 52 to week 76
AAD: Lebrikizumab Shows Efficacy in Skin-of-Color Patients With Atopic Dermatitis
Among patients with atopic dermatitis and self-reported race other than White, 68.3 percent achieved EASI 75 at week 16
AAD: Bimekizumab Response Durable at Four Years for Moderate-to-Severe Psoriasis
After four years of bimekizumab treatment, more than six in 10 patients achieved and maintained complete skin clearance
AAD: Adult Acne Clinic Visits Increase With Exposure to Wildfire-Related Air Pollution
Rate of adult acne clinic visits 1.2-fold higher during 2018 California Camp Fire compared with nonfire weeks in 2015 and 2016
AAD: Risk for Second Primary Malignancy Increased for Melanoma Patients
Melanoma survivors at greatest risk for cutaneous melanoma, ocular melanoma, thyroid, brain, prostate cancers
Recommendations Developed for Managing Vitiligo in Young Patients
33 of 42 recommendations obtained 70 percent or higher composite agreement and strong agreement
Atopic Dermatitis in Children Tied to Learning, Memory Difficulties
However, finding limited to children with neurodevelopmental comorbidities, like ADHD or learning disabilities
AAD: Concerns Noted Relating to Use of AI Dermatology Apps
None of the apps are approved by the FDA; only two include disclaimers for lack of regulatory approval
Carcinogen Benzene Can Form in Some Acne Treatments: Report
A new report finds high levels of the carcinogen benzene in acne treatments that contain benzoyl peroxide.
Skin of Color Underrepresented in AI Programs in Dermatology
Challenges in AI and its application to SOC stem from underrepresentation of SOC in datasets, issues with quality, standardization of images
Patients, Observers Tend to Favor 2-OCA Added to Wound Suture
No significant difference seen in scar cosmesis; patients favored 2-OCA for most components of wound care, although trends were not significant
Use of Immunohistochemistry in Melanoma Diagnosis Increased From 2000 to 2017
11 percent of melanoma cases had claims for ICH at or near diagnosis in 2000; this number increased to 51 percent in 2017
24 of 1200